Clinical trials in Caen – page 27

649 clinical trials in Caen, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Caen at a glance

649

clinical trials

Research sites3

Quick filters

649 trials in Caen

Open in trial search

Breast cancer

Not yet recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Camizestrant
Sponsor:AstraZeneca AB

Contact Research Centre

Hypersensitivity pneumonitis

Not yet recruiting

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisolone Metasulfobenzoate Sodium
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo

France

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:Centre Hospitalier Universitaire De Toulouse

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Hip arthroplasty

Not yet recruiting

Study of Doxycycline Bone and Joint Penetration in Patients Undergoing Total Hip Arthroplasty for Hip Osteoarthritis

Registered drugNo placebo

Study of Doxycycline Bone and Joint Penetration in Patients Undergoing Total Hip Arthroplasty for Hip Osteoarthritis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Doxycycline
Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Contact Research Centre

Breast cancer

Not yet recruiting

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cefazolin Sodium
Sponsor:University Hospital Of Clermont-Ferrand

Contact Research Centre

Systemic lupus erythematosus

Not yet recruiting

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Unicancer

Contact Research Centre

Cystic fibrosis

Not yet recruiting

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azithromycin
Sponsor:Centre Hospitalier Intercommunal Creteil

Contact Research Centre

Non-small cell lung cancer stage III

Not yet recruiting

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Pneumonia+1

Not yet recruiting

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospital Region Metz Thionville

Contact Research Centre

Cardiac failure

Not yet recruiting

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Registered drugNo placebo

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetazolamide
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Caen

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on multiple cancer types including head and neck squamous cell carcinoma, endometrial cancer, and multiple myeloma. Studies evaluate novel therapeutic combinations and treatment strategies.

Advanced solid tumors
Hematological malignancies
Gastrointestinal cancers

Trials investigate targeted therapies and immunotherapy approaches for improved patient outcomes.

02 Infectious Disease Research

Studies examining prevention and treatment of respiratory infections, with focus on respiratory syncytial virus (RSV) in vulnerable populations. Investigation of novel antibiotics for prosthetic joint infections.

Viral infections
Bacterial infections
Preventive treatments

Research aims to develop effective preventive strategies and therapeutic interventions.

03 Cardiovascular Medicine

Research exploring treatments for heart failure prevention and management of cardiovascular conditions. Studies evaluate antiplatelet therapy strategies in elderly patients following interventional procedures.

Heart failure
Coronary interventions
Preventive cardiology

Focus on improving cardiovascular outcomes through innovative therapeutic approaches.

Back to France All countries